Literature DB >> 23302755

Muscle dysmorphia: risk may be influenced by goals of the weightlifter.

Karen M Skemp1, Richard P Mikat, Kyle P Schenck, Natalie A Kramer.   

Abstract

Athletes with muscle dysmorphia suffer from constant dissatisfaction with body size and shape because they perceive themselves as smaller and less muscular than they actually are. There may be discrepancies among the various subgroups within the weightlifting community in regards to vulnerability and susceptibility to the development of MD. The purpose of this study, therefore, was to examine and compare MD symptomology between male and female, competitive and noncompetitive, and appearance-related and performance-related weightlifters. The MD assessments were made with the muscle dysmorphia inventory (MDI). The participants included 85 competitive (55 men and 30 women) and 48 noncompetitive (24 men and 24 women) weight training athletes. Each group included athletes with a primary focus on appearance enhancement or performance enhancement. Factorial analyses of variance were used to measure differences between each group on all MDI subscales. The results showed that men scored significantly higher than did women on the supplement (p = 0.006), physique protection (p = 0.039), and body size and symmetry subscales (p < 0.001). Competitive athletes scored significantly higher than noncompetitive athletes did on diet (p < 0.001), supplement (p < 0.001), exercise dependence (p < 0.001), and body size and symmetry (p = 0.002) subscales. Finally, the athletes focused on appearance enhancement scored significantly higher than athletes focused on performance enhancement on all 6 subscales (p < 0.01). Coaches and health and fitness professionals should understand that the goals of athletes in regard to weight training can influence susceptibility to development of MD symptoms. Knowing that athletes who engage in weight training to enhance appearance may exhibit greater behavioral characteristics than those athletes who do not may be helpful so they may be able to identify, prevent, and reverse MD in the athletes they serve.

Entities:  

Mesh:

Year:  2013        PMID: 23302755     DOI: 10.1519/JSC.0b013e3182825474

Source DB:  PubMed          Journal:  J Strength Cond Res        ISSN: 1064-8011            Impact factor:   3.775


  6 in total

Review 1.  Muscle Dysmorphia Symptomatology and Associated Psychological Features in Bodybuilders and Non-Bodybuilder Resistance Trainers: A Systematic Review and Meta-Analysis.

Authors:  Lachlan Mitchell; Stuart B Murray; Stephen Cobley; Daniel Hackett; Janelle Gifford; Louise Capling; Helen O'Connor
Journal:  Sports Med       Date:  2017-02       Impact factor: 11.136

Review 2.  Muscle dysmorphia: current insights.

Authors:  David Tod; Christian Edwards; Ieuan Cranswick
Journal:  Psychol Res Behav Manag       Date:  2016-08-03

3.  Understanding exercise addiction, psychiatric characteristics and use of anabolic androgenic steroids among recreational athletes - An online survey study.

Authors:  Björn Gunnarsson; Artin Entezarjou; Fernando Fernández-Aranda; Susana Jiménez-Murcia; Göran Kenttä; Anders Håkansson
Journal:  Front Sports Act Living       Date:  2022-08-01

4.  Validation of the Muscle Dysmorphic Disorder Inventory (MDDI) among Italian Women Practicing Bodybuilding and Powerlifting and in Women Practicing Physical Exercise.

Authors:  Silvia Cerea; Matteo Giraldo; Corrado Caudek; Gioia Bottesi; Antonio Paoli; Marta Ghisi
Journal:  Int J Environ Res Public Health       Date:  2022-08-02       Impact factor: 4.614

5.  Enhancing the Self: Amateur Bodybuilders Making Sense of Experiences With Appearance and Performance-Enhancing Drugs.

Authors:  Juraj Macho; Jiri Mudrak; Pavel Slepicka
Journal:  Front Psychol       Date:  2021-06-11

6.  Muscle Dysmorphia and its Associated Psychological Features in Three Groups of Recreational Athletes.

Authors:  Silvia Cerea; Gioia Bottesi; Quirico F Pacelli; Antonio Paoli; Marta Ghisi
Journal:  Sci Rep       Date:  2018-06-11       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.